FRNM · Freenome, Inc.
$13.04
+0.32 (+2.52%)
At close · Oct 27
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jul 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company's liquidity condition and mandatory liquidation raise substantial doubt about the Company's ability to continue as a going concern for a period of time within one year after the date that the accompanying unaudited condensed consolidated financial statements are issued. Management plans to address this uncertainty through a Business Combination. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after the Combination Period. The Company intends to complete the initial Business Combination before the end of the Combination Period. However, there can be no assurance that the Company will be able to consummate any Business Combination by the end of the Combination Period, including if the combination Period is further extended upon approval of the Extension Amendment Proposal.”View the 10-Q filed Jul 15, 2026
Market Cap
$131.19M
Shares
10.31M
Volume · Oct 27
513.18K
Avg daily vol (3M)
846.4K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.04
Open$12.74
Day$12.57–13.43
52W close$9.99–17.11
Avg vol 30d846K
Short int4.5M · 43.5% float · 5.6d
Short vol34%
DataJun 2024–Oct 2026
Filing10-Q · Jul 15
Latest filings
8-K
Regulation FD disclosure
·
filed Oct 20, 2026
Freenome launched SimpleScreen Lung, enabling eligible patients to receive lung and colorectal cancer screening through a single blood draw. The lung test achieved 85% sensitivity at 50% specificity and a 99.8% negative predictive value.
Read the 8-K
10-Q
filed Jul 15, 2026
Read the 10-Q
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$762,626
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$437,369
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
+19.1%
Trailing year
Short interest
43.5%
Latest settlement · 5.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+4%
above
Price vs 50-day avg
−12%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
43%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−18%
trailing
6-month return
+16%
trailing
YTD return
0%
this year
Relative strength
+11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
4 of 27 funds reported for Sep 30 · net +819.6K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
43.47% of float · ▲ +31.9% MoM · 5.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
27 holders — near 2-yr low, contrarian setup
Squeeze score
77
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
48%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+4%
Bullish
Price vs 50-day avg
−12%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
43%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $15 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
4 of 27 funds reported for Sep 30 · net +819.6K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
43.47% of float · ▲ +31.9% MoM · 5.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
27 holders — near 2-yr low, contrarian setup
Price context
position in its 52-week range
Range low $10
Now $13 · 43%
Range high $17
vs 200-day avg +4%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FRNM
this stock
Freenome, Inc.
|
$131.19M | +0.1% | — | — | 43.5% |
|
TMO
Thermo Fisher Scientific Inc.
|
$256.84B | +19.6% | +14.5% | 37.4 | 1.3% |
|
DHR
Danaher Corp
|
$163.90B | +1.3% | +8.5% | 38.1 | 1.2% |
|
NTRA
Natera, Inc.
|
$58.36B | +79.3% | -2.8% | — | 4.1% |
|
A
Agilent Technologies, Inc.
|
$50.34B | +30.4% | +6.4% | 35.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 20, 2026
- This year
- 18
Freenome launched SimpleScreen Lung, enabling eligible patients to receive lung and colorectal cancer screening through a single blood draw. The lung test achieved 85% sensitivity at 50% specificity and a 99.8% negative predictive value.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FRNM | -7.3% | -18.1% | +15.5% | -17.2% | +0.1% |
| SPY | +0.1% | +0.7% | +4.9% | +0.9% | +12.9% |
| vs SPY | -7.3% | -18.8% | +10.6% | -18.1% | -12.8% |